KC 11404
Latest Information Update: 06 Dec 2006
Price :
$50 *
At a glance
- Originator Kali-Chemie
- Class Anti-inflammatories; Antiasthmatics; Piperazines; Small molecules
- Mechanism of Action 5-lipoxygenase inhibitors; Histamine H1 receptor antagonists; Platelet activating factor inhibitors
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
Highest Development Phases
- Discontinued Asthma
Most Recent Events
- 30 May 2001 Profile reviewed but no significant changes made
- 31 Aug 1998 No-Development-Reported for Asthma in Netherlands (unspecified route)
- 14 Jun 1995 Preclinical development for Asthma in Netherlands (unspecified route)